DE69913548T2 - Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen - Google Patents

Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen Download PDF

Info

Publication number
DE69913548T2
DE69913548T2 DE69913548T DE69913548T DE69913548T2 DE 69913548 T2 DE69913548 T2 DE 69913548T2 DE 69913548 T DE69913548 T DE 69913548T DE 69913548 T DE69913548 T DE 69913548T DE 69913548 T2 DE69913548 T2 DE 69913548T2
Authority
DE
Germany
Prior art keywords
pain
mglur
mglur5
antagonists
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69913548T
Other languages
German (de)
English (en)
Other versions
DE69913548D1 (de
Inventor
Hans Allgeier
David Nicholas COSFORD
Josef Peter FLOR
Fabrizio Gasparini
Conrad Gentsch
D. Stephen HESS
Carl Edwin JOHNSON
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Andrew Mark VARNEY
Gönül VELI ELEBI
Katharine Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
SIBIA Neurosciences Inc
Original Assignee
Novartis AG
SIBIA Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69913548(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis AG, SIBIA Neurosciences Inc filed Critical Novartis AG
Application granted granted Critical
Publication of DE69913548D1 publication Critical patent/DE69913548D1/de
Publication of DE69913548T2 publication Critical patent/DE69913548T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DE69913548T 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen Revoked DE69913548T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
GB9821503 1998-10-02
US22081398A 1998-12-23 1998-12-23
US220813 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (2)

Publication Number Publication Date
DE69913548D1 DE69913548D1 (de) 2004-01-22
DE69913548T2 true DE69913548T2 (de) 2004-09-23

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69913548T Revoked DE69913548T2 (de) 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Country Status (21)

Country Link
EP (1) EP1117403B1 (https=)
JP (1) JP2002526408A (https=)
KR (1) KR20010088832A (https=)
CN (1) CN1187048C (https=)
AT (1) ATE255894T1 (https=)
AU (1) AU765644B2 (https=)
BR (1) BR9914215A (https=)
CA (1) CA2345137A1 (https=)
DE (1) DE69913548T2 (https=)
DK (1) DK1117403T3 (https=)
ES (1) ES2213389T3 (https=)
HU (1) HUP0200553A3 (https=)
ID (1) ID29095A (https=)
IL (2) IL142047A0 (https=)
NO (1) NO20011440L (https=)
NZ (1) NZ510743A (https=)
PL (1) PL202906B1 (https=)
PT (1) PT1117403E (https=)
RU (1) RU2232017C2 (https=)
SK (1) SK4382001A3 (https=)
WO (1) WO2000020001A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
PT1345609E (pt) 2000-12-22 2005-08-31 Hoffmann La Roche Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
LT3303316T (lt) 2015-06-03 2020-05-11 F. Hoffmann-La Roche Ag Etinilo dariniai
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
BR9914215A (pt) 2001-07-03
CA2345137A1 (en) 2000-04-13
NZ510743A (en) 2003-10-31
ES2213389T3 (es) 2004-08-16
NO20011440D0 (no) 2001-03-21
KR20010088832A (ko) 2001-09-28
CN1187048C (zh) 2005-02-02
NO20011440L (no) 2001-05-15
EP1117403A1 (en) 2001-07-25
EP1117403B1 (en) 2003-12-10
IL142047A0 (en) 2002-03-10
AU6198499A (en) 2000-04-26
HUP0200553A2 (hu) 2002-07-29
ID29095A (id) 2001-07-26
JP2002526408A (ja) 2002-08-20
CN1321087A (zh) 2001-11-07
PL346876A1 (en) 2002-03-11
SK4382001A3 (en) 2001-08-06
AU765644B2 (en) 2003-09-25
PT1117403E (pt) 2004-04-30
RU2232017C2 (ru) 2004-07-10
IL142047A (en) 2007-09-20
DE69913548D1 (de) 2004-01-22
HUP0200553A3 (en) 2002-11-28
WO2000020001A1 (en) 2000-04-13
PL202906B1 (pl) 2009-08-31
ATE255894T1 (de) 2003-12-15
DK1117403T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
DE69913548T2 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
EP2206498B9 (de) Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE69001503T2 (de) D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.
Carter et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.
DE3876877T2 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE60103384T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
DE69833451T2 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
DE68928920T2 (de) Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
DE69936992T2 (de) Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker
US20040006120A1 (en) Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
DE69626610T2 (de) Produkt enthaltend Rapamycin oder ausgewählte Derivate und einen NMDA- oder AMPA-Antagonisten zur Verwendung für die Behandlung von Epilepsie oder Morbus Huntington, und die Verwendung von Rapamycin oder von ausgewählten Derivaten für die Herstellung eines Medikaments für die Behandlung von Epilepsie oder Morbus Huntington.
DE69933874T2 (de) Topische zusammensetzung enthaltend ein opioid-analgetika und einen nmda-antagonist
Khatri et al. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.
DE69837387T2 (de) (d)-METHADON, EIN NICHT-OPIOIDES SCHMERZMITTEL
EP0193056A1 (de) Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
Keegan Muscle relaxants and neuromuscular blockade
Kuhn et al. Stimulus properties of the narcotic antagonist pentazocine: similarity to morphine and antagonism by naloxone.
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
DE69933450T2 (de) Imidazolin-rezeptor-bindende verbindungen
DE102007018150A1 (de) VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz
Lorrai et al. Reducing effect of the novel positive allosteric modulator of the GABAB receptor, COR659, on binge-like alcohol drinking in male mice and rats
EP0516795B1 (de) Arzneimittel enthaltend einen quisqualat-rezeptor-antagonisten und einen dopamin-agonisten zur behandlung des morbus parkinson
DE60213365T2 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
CA2044854A1 (en) Method for preventing or treating urinary incontinence
Gullikson et al. Gastrointestinal motility responses to the S and R enantiomers of zacopride, a 5‐HT4 agonist and 5‐HT3 antagonist

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8331 Complete revocation